Dysregulation of fibrosis related genes in HCV induced liver disease

Dawood, Reham M.; El-Meguid, Mai Abd; Ibrahim, Marwa K.; Din, Noha G Bader El; Barakat, Ahmed B.; El-Wakeel, Khaled; Alla, Mohamed Darwish Ahmed Abd; Wu, George Y.; Awady, Mostafa K. El

doi:10.1016/j.gene.2018.04.032

Cited by 15 publications

(6 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most genes associated with hepatitis have been previously implicated in the pathogenesis of various liver diseases. For example, TGIF1 (TGFB-induced factor homeobox 1) is shown to be up-regulated in patients with hepatitis C virus infection [ 35 , 36 ], but down-regulated in fibrotic liver patients [ 37 ]. A study of patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma showed that the FAT4 (FAT atypical cadherin 4) gene might act as a tumor suppressor gene, which is inactivated in cases with hepatocellular carcinoma, but also in various other human cancers [ 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

Genome-Wide Meta-Analysis Identifies Multiple Novel Rare Variants to Predict Common Human Infectious Diseases Risk

Gelemanović

Ardalić

Pribisalić

et al. 2023

IJMS

View full text Add to dashboard Cite

Infectious diseases still threaten global human health, and host genetic factors have been indicated as determining risk factors for observed variations in disease susceptibility, severity, and outcome. We performed a genome-wide meta-analysis on 4624 subjects from the 10,001 Dalmatians cohort, with 14 infection-related traits. Despite a rather small number of cases in some instances, we detected 29 infection-related genetic associations, mostly belonging to rare variants. Notably, the list included the genes CD28, INPP5D, ITPKB, MACROD2, and RSF1, all of which have known roles in the immune response. Expanding our knowledge on rare variants could contribute to the development of genetic panels that could assist in predicting an individual’s life-long susceptibility to major infectious diseases. In addition, longitudinal biobanks are an interesting source of information for identifying the host genetic variants involved in infectious disease susceptibility and severity. Since infectious diseases continue to act as a selective pressure on our genomes, there is a constant need for a large consortium of biobanks with access to genetic and environmental data to further elucidate the complex mechanisms behind host–pathogen interactions and infectious disease susceptibility.

show abstract

Section: Discussionmentioning

confidence: 99%

Genome-Wide Meta-Analysis Identifies Multiple Novel Rare Variants to Predict Common Human Infectious Diseases Risk

Gelemanović

Ardalić

Pribisalić

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…These were the transforming growth factor beta (TGFβ)-related pathway genes and Matrix-deposition associated genes. These were considerably over-expressed at transcriptional levels as early as F0 (13).…”

Section: Discussionmentioning

confidence: 99%

Association of Equiliberative Nucleoside Transporter (ENT) with liver fibrosis stage in Hepatitis-C

Bhatti¹,

Syed²,

Ujjan³

2022

J Pak Med Assoc

View full text Add to dashboard Cite

Objective: To evaluate the pattern of equiliberative nucleoside transporters in viral hepatitis responding and non-responding patients, to correlate the liver fibrosis stage with the pattern among the non-responders, and to correlate the equiliberative nucleoside transporter status with housekeeping hypoxanthine-guanine phosphoribosyltransferase gene. Method: The comparative cross-sectional study was conducted at the Molecular Biology and Genetics Department, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan, from March to August 2018, and comprised adult hepatitis C virus patients of either gender who completed six months of treatment. They were assessed for response to therapy in terms of the presence of the viral load in their serum by using real time polymerase chain reaction, and divided into responder group A and non-responder group B. The groups were compared and correlation between equiliberative nucleoside transporter expressions and liver fibrosis was evaluated. Data was analysed using SPSS 23. Results: Of the 80 patients, 33(41.3%) were males and 47(58.8%) were females. The overall mean age was 37.46±10.61 years. In terms of response to treatment, there were 40(50%) in each of the two groups. Mean post-treatment duration was 15.38±30.09 weeks. Age was not significantly different with respect to gender (p>0.05), but the age pattern was significantly different between the two groups (p<0.001). Also, non-responders had significant post-treatment duration compared to the responders (p<0.001). Hypoxanthine-guanine phosphoribosyltransferase gene showed no significant difference between the groups (p=0.144). ---Continue

show abstract

“…In the era of oral DAAs combination therapies, the positive feedback of the CC IL-28β genotype varies by type of treatment regimen (26) . IL-28, which activates interferon-stimulated genes, is the orchestra maestro of innate immunity against HCV burden (27) . So, the present study, which achieved SVR12 rate of 97% in overall patients, covers the most patients that had non-CC IL-28β genotype (77%), suggesting that this host genotype does not have negative feedback on the virological outcome when treated with the current therapy.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Ombitasvir with Paritaprevir/Ritonavir plus Ribavirin on the Treatment of Naïve Patients with Chronic Hepatitis C Virus Genotype 4

Abdel-GAbbar¹,

Alkot²,

Abdel-Moneim³

2022

IJPS

View full text Add to dashboard Cite

Background Direct-acting antivirals (DAAs) combination therapies from various mechanisms of action and families have been revolutionized the management landscape of chronic hepatitis C virus (HCV). Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) ± ribavirin (RBV) is approved to treat HCV genotype 4 (GT4) infection. Here, our objective was to delineate the efficacy and safety of OBV/PTV/r plus RBV in treating of Egyptian naïve patients infected with HCV GT4. Methods a cohort of 100 Egyptian patients infected with HCV GT4 was allocated and administered orally OBV/PTV/r with RBV. The primary endpoint of our study was a sustained virological response (HCV RNA < 12 IU/mL) 12 weeks after the cessation of the treatment (SVR12). This study is registered with ClinicalTrials.gov, number NCT04378608. Results Among treatment naïve patients with OBV/PTV/r+ RBV, SVR12 rates achieved 97% (97/100) in overall patients. Regarding treatment failure, the regimen recorded 3 % had treatment failure (0 null-responses, 3 relapses). However, the most frequently common adverse events recorded were a headache (28%), fatigue (18%), asthenia (23%), nausea (19%) and dyspnea (14%). Conclusions The interferon-free regimen combination of OBV/PTV/r plus RBV achieved excellent SVR12 rates, 97%, with virologic outcome failures 3%, and it was generally safe and well tolerated for treating naïve patients infected with HCV GT4.

show abstract

Dysregulation of fibrosis related genes in HCV induced liver disease

Cited by 15 publications

References 72 publications

Genome-Wide Meta-Analysis Identifies Multiple Novel Rare Variants to Predict Common Human Infectious Diseases Risk

Genome-Wide Meta-Analysis Identifies Multiple Novel Rare Variants to Predict Common Human Infectious Diseases Risk

Association of Equiliberative Nucleoside Transporter (ENT) with liver fibrosis stage in Hepatitis-C

Effectiveness of Ombitasvir with Paritaprevir/Ritonavir plus Ribavirin on the Treatment of Naïve Patients with Chronic Hepatitis C Virus Genotype 4

Contact Info

Product

Resources

About